Related Experiment Video
Updated: Jan 12, 2026

A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery
Published on: January 18, 2018
Prevalence and Predictors of Early Response to Adjunct Methadone for Cancer-Related Pain in Palliative Care
Kenny Kwon Ho Lee1,2, Amanda Johns3, Wei Lee4,5,6,7
1Sydney School of Pharmacy, Faculty of Medicine and Health Sciences, The University of Sydney, Sydney, Australia.
Background:
Adjunct methadone has been used previously for cancer-related pain, but evidence on predictors for early response remains limited.
Objective:
Identify the prevalence and predictors of early adjunct methadone response in palliative care patients.
Design:
Retrospective cohort study.
Settings/Subjects:
Patients who initiated adjunct methadone from 2022 to 2024.
Measurement:
Univariate and multivariate Poisson regression identified prevalence and predictors of early response.
Results:
Among 42 patients, 28 (67%) achieved early response. They had higher baseline oral morphine equivalents, higher starting methadone doses, and shorter days to first titration (p < 0.05). Predictors included metastatic cancer (RR 3.30, p = 0.005), higher performance status (RR 2.58, p = 0.033), methadone daily dose >5 mg (RR 3.91, p = 0.013), lower baseline pain scores (RR 0.78, p = 0.025), and preserved liver function (RR 4.32, p = 0.009).
Conclusion:
Metastatic cancer patients with high performance status without liver damage may benefit from a higher, proactively titrated starting dose of adjunct methadone.
More Related Videos
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Therapeutic Drug Monitoring: Affecting Factors